🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Recombinant NY-ESO-1 Protein

Found 15 matching trials

Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer

PHASE1

This phase I clinical trial evaluates the safety and feasibility of adminis...

Status

Terminated

Location

UCLA / Jonsson Comprehensive Cancer Center

Start Date

2017-07-26

Trial ID

NCT03240861

Treatments Being Tested

18F-FHBG Aldesleukin Busulfan Cellular Therapy Computed Tomography Filgrastim Fludarabine Leukapheresis Plerixafor Positron Emission Tomography

Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

PHASE1

This phase I trial studies the best dose and side effects of NY-ESO-1 T cel...

Status

Terminated

Location

Roswell Park Cancer Institute

Start Date

2019-03-08

Trial ID

NCT03691376

Treatments Being Tested

Aldesleukin Autologous NY-ESO-1-specific CD8-positive T Lymphocytes Cellular Therapy Melphalan

Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies

PHASE1

This pilot phase I trial studies the side effects of taking ipilimumab afte...

Status

Terminated

Location

Jonsson Comprehensive Cancer Center

Start Date

2014-07-17

Trial ID

NCT02070406

Treatments Being Tested

cyclophosphamide fludarabine phosphate NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL dendritic cell vaccine therapy aldesleukin fludeoxyglucose F 18 positron emission tomography laboratory biomarker analysis

Safety Study of a Recombinant Protein Vaccine to Treat Esophageal Cancer

PHASE1

The purpose of this study is to determine the biological recommended dose o...

Status

Completed

Location

Aichi Cancer Center Hospital

Start Date

2009-11

Trial ID

NCT01003808

Treatments Being Tested

IMF-001

A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer

PHASE1

This is a Phase I, multi-center, multiple ascending dose study to evaluate ...

Status

Completed

Location

Scottsdale Healthcare

Start Date

2013-11

Trial ID

NCT02015416

Treatments Being Tested

IDC-G305

A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma

PHASE2

This phase II trial studies the effect of a vaccine called CDX-1401 given w...

Status

Completed

Location

University of Chicago Comprehensive Cancer Center

Start Date

2014-04-09

Trial ID

NCT02129075

Treatments Being Tested

DEC-205/NY-ESO-1 Fusion Protein CDX-1401 Poly ICLC Recombinant Flt3 Ligand

TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma

PHASE1

This phase I trial studies the side effects of NY-ESO-1 TCR engineered peri...

Status

Withdrawn

Location

UCLA / Jonsson Comprehensive Cancer Center

Start Date

2018-07-10

Trial ID

NCT03506802

Treatments Being Tested

18F-FHBG Aldesleukin Cellular Therapy Computed Tomography Filgrastim Laboratory Biomarker Analysis Lenalidomide Leukapheresis Melphalan Plerixafor Positron Emission Tomography

Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)

PHASE1

The goal of this Phase I/II observational and interventional platform study...

Status

Not Yet Recruiting

Location

Multiple Locations

Start Date

2026-01-01

Trial ID

NCT07307053

Treatments Being Tested

BL-B01D1 VSV injection CVL006 IDOV-SAFE KXV01 TCR Lentinvivo Injection MT027 QH101 Meta10-TIL TAEST1901 TC-N201 NK510 CE120 GV20-0251 LYC001 YSCH-01 BMD006 CREPT-618 PRG2505 IBI363 YL-201

Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes

EARLY_PHASE1

This pilot clinical trial studies the side effects of anti-ESO (cancer/test...

Status

Terminated

Location

Albert Einstein College of Medicine

Start Date

2017-04-20

Trial ID

NCT02774291

Treatments Being Tested

Aldesleukin Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes Cyclophosphamide Filgrastim Fludarabine Phosphate Laboratory Biomarker Analysis

Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

PHASE1

This phase I clinical trial studies the side effects of sirolimus and NY-ES...

Status

Withdrawn

Location

Roswell Park Cancer Institute

Start Date

2017-12-08

Trial ID

NCT02833506

Treatments Being Tested

Laboratory Biomarker Analysis Recombinant NY-ESO-1 Protein Sirolimus

Previous Next